

ACKNOWLEDGEMENT

Acknowledgement to Referees

© Springer Nature Switzerland AG 2021

Dear Reader,

Welcome to the final issue of *Clinical Drug Investigation* for 2021.

I wish to reflect on this year's achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal.

In 2021, over 105 articles have been published. The most popular of these in terms of downloads from SpringerLink have been:

Sagili Anthony DP, Sivakumar K, Venugopal P, et al. Can mRNA vaccines turn the tables during the COVID-19 pandemic? Current status and challenges. *Clin Drug Investig* 41:499–509 (2021). <https://doi.org/10.1007/s40261-021-01022-9>

Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. *Clin Drug Investig* 41:303–319 (2021). <https://doi.org/10.1007/s40261-021-01000-1>

Giustozzi M, Mazzetti M, Paciaroni M, et al. Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation. *Clin Drug Investig* 41, 43–51 (2021). <https://doi.org/10.1007/s40261-020-00982-8>

De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. *Clin Drug Investig* 41:425–436 (2021). <https://doi.org/10.1007/s40261-021-01032-7>

von Wrede R, Helmstaedter C, Surges R. Cannabidiol in the treatment of epilepsy. *Clin Drug Investig* 41:211–220 (2021). <https://doi.org/10.1007/s40261-021-01003-y>

The high quality of content published in *Clinical Drug Investigation* has been reflected in the most recent impact factor of 2.859 and CiteScore™ of 4.3. Further, *Clinical Drug Investigation* has published content in a timely manner, with an average time from submission to first decision of 22 days.

The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.

I would like to start by thanking the authors of the articles published in *Clinical Drug Investigation* over the course of 2021. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.

The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for *Clinical Drug Investigation* in the last 12 months:

Armina Abbasi, USA
Mahmoud H. Abdelnabi, Egypt
Sravani Adusumalli, USA
Antonia Agustí, Spain
Manabu Akazawa, Japan
Alberto Albanese, Italy
Jaime Algorta, Spain
Loubna Alj, Morocco
Mohammad Alkhalil, UK
Rieke Alten, Germany
Sabina A. Antoniu, Romania
Kazuhiro Araki, Japan
Gonzalo E. Aranda-Abreu, Mexico
Ronen Arbel, Israel
Ozer Arican, Turkey
Gregory M. Asnis, USA
Abdullah Assiri, Saudi Arabia
Fabio Badilini, Italy
Andrea Becciolini, Italy
Gaetano Bertino, Italy
Alessandra Bettiol, Italy
Annalisa Biffi, Italy
Watchara Boonsawat, Thailand
Denis Boucaud-Maitre, Guadeloupe
Nicholas Britt, USA
Koon Ho Chan, Hong Kong, China
Soumya G. Chikermane, USA
David B. Cluck, USA
Pier Giorgio Cojutti, Italy
Helena H. Colom, Spain
Vincent J. Colucci, USA
Andrea Conti, Italy
David Coppini, UK
Michele Correale, Italy
Antonio Cuneo, Italy
Giovanni Damiani, Italy
Ranjeet P. Dash, USA
Andrew P. Demidowich, USA
Giovan Giuseppe Di Costanzo, Italy
Michael J. Dickinson, USA
Igor Diemberger, Italy
Lorena Dima, Romania
Jasper Dingemanse, Switzerland
Thomas Dirschka, Germany
Karim Dorgham, France
Murray P. Ducharme, Canada
Ahmed El-Zawahry, USA
Maura Faraci, Italy
Pietro Ferrara, Italy
Roberto Ferrari, Italy
Ryan Field, USA
Kohei Fujita, Japan
Motohiro Fujiwara, Japan
Michele Fusaroli, Italy
Luca Gallelli, Italy
Marco Galluzzo, Italy
Pere Gascon, Spain
Andrea Giacomelli, Italy
Anna Gigli, Italy
Lara Gitto, Italy
Michela Giustozzi, Italy
Tomasz Grabowski, Poland
Myfanwy Graham, Australia
Alois Gratwohl, Switzerland
Ruichen Guo, China
Francisco Javier A. Gutiérrez, Spain
Staffan Hägg, Sweden
Yasuhiro Hagiwara, Japan
Masayoshi Harigai, Japan
Sam Harirforoosh, USA
Francisco J. Hidalgo, Spain
Andrew Hill, UK
Sarah A. Holstein, USA
Keiko Hosohata, Japan
Florenzo Iannone, Italy
Yoichi Imai, Japan
Kevin Ita, USA
Lyndon James, USA
Rohitash Jamwal, USA
Slobodan M. Jankovic, Serbia
Hongli Jiang, China
Zheng Jiao, China
Ted Johnson, USA
Karissa M. Johnston, Canada
Bruce M. Jones, USA
Sushil K. Kabra, India
Ekta Kadakia, USA
Siva Rama Raju Kanumuri, USA
Jonathan Karnon, Australia
Masami Kawahara, Japan
Adam M. Kaye, USA
Shunsuke Kiuchi, Japan
Shinji Kobuchi, Japan
Stephan Kraehenbuehl, Switzerland
Robert J. Kreitman, USA
Akira Kuriyama, Japan
Valentina Leta, UK
Theresa Leung, Hong Kong, China
Peter A. Lio, USA
David M. Mannino, USA
Louise-Laure Mariani, France
Paolo Martelletti, Italy
Ann McCormack, Australia
Andrea Melani, Italy
Cristiane A. Menezes de Padua, Brazil
Gideon Meyerowitz-Katz, Australia

Denise Miyamoto, Brazil
 Aliae A. R. Mohamed Hussein, United Arab Emirates
 Luca Monzo, Italy
 Alessandro Morabito, Italy
 Digvijaya Navalkele, USA
 Hoa Q. Nguyen, USA
 Bettina N. Nielsen, Denmark
 Yoshihiro Noguchi, Japan
 Keumhan Noh, Canada
 Achilles Ntranos, USA
 Shunsuke Ono, Japan
 Kent A. Owusu, USA
 Dimitrios Papadopoulos, Cyprus
 Nikolaos Papanas, Greece
 Elisabeth Paramythiotou, Greece
 Nisha V. Parmar, United Arab Emirates
 Hiten Patel, USA
 Nimish Patel, USA
 Peter E. Penson, UK
 Panagiotis Petrou, Cyprus
 Marion Plaze, France
 Camille Ponte, France
 Paolo Ragonese, Italy
 Umberto Restelli, Italy
 Alessandro Rizzo, Italy
 Federica Rizzo, Italy
 Tadeusz Robak, Poland
 Jonathan L. Robbins, USA
 Madhav Sachar, USA
 Takamasa Sakai, Japan
 Jonas B. Sandbrink, UK
 Bjoern Schwander, Germany
 Lei Sheng, China
 Yin Shi, China
 Yoshimitsu Shimomura, Japan
 Neal Shore, USA
 Spyridon Siafis, Germany
 Dawid Sigorski, Poland
 Rafael Simó, Italy
 Mahmoud Slim, Spain
 Bastiaan Sol, Belgium
 Yu-Hu Song, China
 Federico Spandonaro, Italy
 Michael Spartalis, Italy
 Jenny Spencer, USA
 Edoardo Spina, Italy
 Kannan Sridharan, Bahrain
 Richard R. Stark, Australia
 Amber Streifel, USA
 Jan Styczynski, Poland
 Harm A. Tiddens, the Netherlands
 Svetlana Tomic, Croatia
 Vladimir Trkulja, Croatia
 Asha Tyagi, India
 Julia Vaamonde, Spain
 Martijn van Noorden, the Netherlands
 Sakalis Vasileios, Greece
 Juan F. Vázquez-Costa, Spain
 Vijayabhaskar Veeravalli, USA
 Cheng-Hsu Wang, Taiwan, Republic of China
 Rene Westhovens, Belgium
 Daniel Wolff, Germany
 Teddy Y. Wu, New Zealand
 Wei Xiaoxia, China
 Shanshan Xu, China
 Li Yang, China
 Dae Hyun Yoo, Republic of Korea
 Ichiro Yoshii, Japan
 Hiroshige Yoshioka, Japan
 Gisele Zandman-Goddard, Israel
 Nava Zisapel, Israel
 Deborah Zvosec, USA

I am also very grateful to the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes.

Ratan K. Banik, Minneapolis, USA
 Edouard Battegay, Basel, Switzerland
 Ettore Beghi, Milan, Italy
 E. Berardesca, Miami, FL, USA
 Lothar Bergmann, Frankfurt, Germany
 L. Bertilsson, Stockholm, Sweden
 Hasan Bhally, Auckland, New Zealand
 B. Brüggjenjürgen, Berlin, Germany
 S. George Carruthers, Lisburn, Northern Ireland
 Jongwha Chang, El Paso, TX, USA
 Andrea Chiricozzi, Pisa, Italy
 Enno Christophers, Kiel, Germany
 Mervyn J. Eadie, Brisbane, QLD, Australia
 Daniel E. Furst, Los Angeles, CA, USA
 Helen Giamarellou, Athens, Greece
 Sylvain Goutelle, Lyon, France
 Yoshiyuki Hamamoto, Osaka, Japan
 Philip D. Home, Newcastle upon Tyne, England
 Emilie Jouanjus, Toulouse, France
 Gregory L. Kearns, Scottsdale, AZ, USA
 Tony K.L. Kiang, Edmonton, ALB, Canada
 Filip K. Knop, Hellerup, Denmark

Evangelos Liberopoulos, Ioannina, Greece
Jörn Lötsch, Frankfurt, Germany
Giovanni Maconi, Milan, Italy
Howard I. Maibach, San Francisco, CA, USA
Ishak A. Mansi, Dallas, TX, USA
Andrea Marcellusi, Rome, Italy
Massimo C. Mauri, Milan, Italy
Natalie Medlicott, Dunedin, New Zealand
Trefor O. Morgan, Melbourne, Vic., Australia
George L. Morris III, Milwaukee, WI, USA
Franco M. Muggia, New York, NY, USA
Mamoru Narukawa, Tokyo, Japan
Nuria Pérez Álvarez, Barcelona, Spain
Emilio Perucca, Melbourne, VIC, Australia
Emanuel Raschi, Bologna, Italy
Matteo Ruggeri, Rome, Italy
Gabriele Sani, Rome, Italy
Shiv K. Sarin, New Delhi, India
Steven C. Schachter, Boston, MA, USA
Marcus Schmitt-Egenolf, Umeå, Sweden
Lee P. Shulman, Northbrook, IL, USA
Jaydeep Sinha, Chapel Hill, NC, USA
Tracy L. Skaer, Spokane, WA, USA
Christine Staatz, Woolloongabba, QLD, Australia
Gianluca Trifirò, Messina, Italy
Peter Tugwell, Ottawa, ONT, Canada
Vivian T. Wong, Hong Kong, China
Bin Wu, Shanghai, China
Hong-Guang Xie, Nanjing, China
Hirosuke Yamaji, Okayama, Japan
Hongxin Zhao, Beijing, China

Springer Nature has continued to support the global response to COVID-19 by making all relevant content immediately and freely available. Indeed, *Clinical Drug Investigation* has published a number of papers relevant to the COVID-19 pandemic that are free to access, including:

Debrabant K, Grønbaek L, Kronborg C. The cost-effectiveness of a COVID-19 vaccine in a Danish context. *Clin Drug Investig* 41:975–988 (2021). <https://doi.org/10.1007/s40261-021-01085-8>

Abdelwahab HW, Shaltout SW, Sayed Ahmed HA, et al. Acetylsalicylic acid compared with enoxaparin for the prevention of thrombosis and mechanical ventilation in COVID-19 patients: a retrospective cohort study. *Clin Drug Investig* 41:723–732 (2021). <https://doi.org/10.1007/s40261-021-01061-2>

Sagili Anthony DP, Sivakumar K, Venugopal P, et al. Can mRNA vaccines turn the tables during the COVID-19 pandemic? Current status and challenges. *Clin Drug Investig* 41:499–509 (2021). <https://doi.org/10.1007/s40261-021-01022-9>

Hoertel N, Sánchez-Rico M, Vernet R, et al. Observational study of chlorpromazine in hospitalized patients with COVID-19. *Clin Drug Investig* 41:221–233 (2021). <https://doi.org/10.1007/s40261-021-01001-0>

Streicher C, Engalenc X, Gaudin M, et al. Could tocilizumab be an attractive therapeutic option for elderly patients with severe COVID-19? A case report. *Clin Drug Investig* 40:1085–1088 (2020). <https://doi.org/10.1007/s40261-020-00969-5>

Charpiat B, Bleyzac N, Tod M. Proton pump inhibitors are risk factors for viral infections: even for COVID-19? *Clin Drug Investig* 40:897–899 (2020). <https://doi.org/10.1007/s40261-020-00963-x>

Bleyzac N, Goutelle S, Bourguignon L, et al. Azithromycin for COVID-19: more than just an antimicrobial? *Clin Drug Investig* 40:683–686 (2020). <https://doi.org/10.1007/s40261-020-00933-3>

Das S, Bhowmick S, Tiwari S, et al. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19). *Clin Drug Investig* 40:591–601 (2020). <https://doi.org/10.1007/s40261-020-00927-1>

Zhang S, Li L, Shen A, et al. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. *Clin Drug Investig* 40: 511–518 (2020). <https://doi.org/10.1007/s40261-020-00917-3>

In terms of other important company initiatives, the Springer Nature ‘Sustainable Development Goals (SDG) Programme’ is aiming to connect researchers who are tackling the world’s toughest challenges with practitioners in policy and business, while the ‘Women in Science’ initiative aims to help empower more women scientists to achieve scientific excellence. Finally,

I am delighted to inform you that Springer Nature is now carbon neutral for its direct operations (offices, fleet and flights) and earlier this year signed The Climate Pledge, making a commitment to be Net Zero carbon by 2040.

Returning to *Clinical Drug Investigation*, the editorial program for 2022 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles over the coming year.

I thank you for your continued support.

With best wishes,

Jasbir Singh